S&P 500: 666.06 -1.5% NASDAQ 100: 597.26 -1.7% Dow Jones: 467.48 -1.5%

Chase Coleman’s HNGE Holdings & Trades

First Buy
Q2 2025
Duration Held
3 Quarters
Largest Add
Q4 2025
+1.25 M Shares
Current Position
1.81 M Shares
$83.88 M Value

Chase Coleman's HNGE Position Overview

Chase Coleman (via Tiger Global Management LLC) currently holds 1.81 M shares of Hinge Health, Inc. (HNGE) worth $83.88 M, representing 0.28% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.

Based on 13F filings, Chase Coleman has maintained this position in HNGE for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 1.25 M shares.

Analysis based on 13F filings available since 2013 Q2

Chase Coleman's Hinge Health (HNGE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Hinge Health (HNGE) Trades by Chase Coleman

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +1.25 M Add 227.12% 1.81 M $46.45
Q2 2025 +552,008 New Buy 552,008 $51.75

Chase Coleman's Hinge Health Investment FAQs

Chase Coleman first purchased Hinge Health, Inc. (HNGE) in Q2 2025, acquiring 552,008 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Chase Coleman has held Hinge Health, Inc. (HNGE) for 3 quarters since Q2 2025.

Chase Coleman's largest addition to Hinge Health, Inc. (HNGE) was in Q4 2025, adding 1,805,751 shares worth $83.88 M.

According to the latest 13F filing for Q4 2025, Chase Coleman's firm, Tiger Global Management LLC, owns 1,805,751 shares of Hinge Health, Inc. (HNGE), valued at approximately $83.88 M.

As of the Q4 2025 filing, Hinge Health, Inc. (HNGE) represents approximately 0.28% of Chase Coleman's publicly disclosed stock portfolio, making it one of their key holdings.

Chase Coleman's peak holding in Hinge Health, Inc. (HNGE) was 1,805,751 shares, as reported at the end of Q4 2025.